Axon reinforces its leadership in the Life Sciences sector with 2 new investments: Forbion & Sofinnova Partners

Aurora, the VC Fund of Fund platform managed by Axon, strengthens its position in this sector in Europe with two new commitments in additional top global Life Sciences funds. 

Aurora has already committed to five Life Sciences funds, with current exposure in the portfolio over 45%. The new investments are a strong fit for the overall fund strategy as they are with top-performing GPs, with consolidated teams, and a consistent strategy.

Forbion is a leading venture capital firm, working closely with entrepreneurs to build Life Sciences companies, applying their technologies and products to transform people’s lives. The GP currently manages over €1 bn across ten closed-end funds. Forbion has a team of thirteen investment professionals across two offices in The Netherlands and Germany, with a multitude of academic accomplishments and a large array of operational experience. This fund will focus on investing in late-stage Life Sciences companies, which look to pass into the final phases of medical trials and/or to list in the U.S. (NASDAQ). It will also encompass investments in companies already listed in the European market but that are looking to relist in the U.S. through PIPEs.

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, with offices in London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S., and Asia. The fund will focus on Growth (Crossover) stage investments in Life Sciences companies, through late-stage equity financing rounds and PIPEs. The fund is managed by a highly-experienced and multi-disciplined team combining years of experience in growth venture and trading/equity analysis. 

Share this post